Cellectis (CLLS) Net Cash Flow Growth (5y) (2020 - 2026)
Cellectis (CLLS) Net Cash Flow Growth (5y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Cellectis | 281.48 Mn | 95.81 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.00% |
| Dec 31, 2025 | -14.07% |
| Sep 30, 2025 | -6.44% |
| Jun 30, 2025 | -19.55% |
| Mar 31, 2025 | 19.05% |
| Dec 31, 2024 | -4.86% |
| Sep 30, 2024 | 17.60% |
| Jun 30, 2024 | 24.32% |
| Mar 31, 2024 | 13.70% |
| Dec 31, 2023 | 37.11% |
| Sep 30, 2023 | -37.84% |
| Jun 30, 2023 | -14.90% |
| Mar 31, 2023 | 16.43% |
| Dec 31, 2022 | 21.00% |
| Sep 30, 2022 | -23.47% |
| Jun 30, 2022 | -8.34% |
| Mar 31, 2022 | -12.14% |
| Dec 31, 2021 | -22.58% |
| Sep 30, 2021 | -49.87% |
| Jun 30, 2021 | 35.21% |